体重指数对评估硼替佐米治疗多发性骨髓瘤周围神经病变发生的价值

The Value of Body Mass Index in Evaluating the Occurrence of Peripheral Neuropathy in Patients with Multiple Myeloma Treated with Bortezomib

摘要: 目的：研究体重指数(Body Mass Index, BMI)在评估硼替佐米治疗多发性骨髓瘤(Multiple Myeloma, MM)中发生周围神经病变(Peripheral Neuropathy, PN)的价值。方法：随机抽样的方法选取潍坊医学院附属医院收治的以硼替佐米为中心治疗的MM患者80例，采集初诊时患者信息，观察并记录患者治疗期间及治疗后硼替佐米相关周围神经病变(Bortezomib-induced peripheral neuropathy, BIPN)的发生情况，进行相关的统计学分析。结果：80例患者中，28例出现BIPN (35%)，且BIPN组BMI高于非BIPN组(P < 0.05)，超重及肥胖组BMI与BIPN的发生率呈正相关(P < 0.05)，而对于BMI <24 kg/m2的患者，体重指数与PN的发生无明显意义(P > 0.05)。结论：在硼替佐米治疗MM过程中，BMI可能与BIPN的发生有关。

Abstract: Objective: The aim of the study was to investigate the value of body mass index in evaluating peripheral neuropathy in patients with multiple myeloma treated with bortezomib. Methods: 80 cases of MM patients treated with bortezomib in the Affiliated Hospital of Weifang Medical University were selected by random sampling method. Collectedthe information of patients at the initial diagnosis, and the occurrence of bortezomib related peripheral neuropathy during and after the treatment was observed and recorded for relevant statistical analysis. Results: Among the 80 patients, 28 cases (35%) had BIPN, and the BMI of BIPN group was higher than that of non-BIPN group (P < 0.05). The BMI of overweight and obesity group was positively correlated with the incidence of BIPN (P < 0.05), but for patients with BMI < 24 kg/m2, there was no significant difference between BMI and the incidence of BIPN (P > 0.05). Conclusion: In the course of bortezomib treatment of MM, BMI may be related to the occurrence of BIPN.